SY-5007
Phase 3Small molecule
SY-5007 is one of 67 small molecule programs targeting Tics. It is currently in Phase 3.
2
Indications
5
Total Trials
3
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
108 competitors in Tics
#DrugCompanyPhaseTrials
1Sodium Valproate
AstraZenecaPhase 3
Priftin
SanofiPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Duvyzat
ItalfarmacoPhase 2
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 2
SY-5007
SShouyao Holdings (Beijing) Co. LTD
Phase 3
Tylenol
KKenvue Brands
Phase 1
Rifampicin
Boehringer IngelheimPhase 1
Abexinostat
XXynomic Pharmaceuticals, Inc.
Phase 2
Anaprazole
SSihuan Pharmaceutical Holdings Group Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics2 trials
Advanced Solid Tumor1 trial
Adult1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SY-5007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details